Stuart E Dryer Selected Research

Segmental glomerulosclerosis

1/2022	TRPC6 Inactivation Reduces Albuminuria Induced by Protein Overload in Sprague Dawley Rats.
10/2021	RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes.
1/2021	Effects of TRPC6 Inactivation on Glomerulosclerosis and Renal Fibrosis in Aging Rats.
3/2019	TRPC6 inactivation does not affect loss of renal function in nephrotoxic serum glomerulonephritis in rats, but reduces severity of glomerular lesions.
10/2018	Mechanisms underlying modulation of podocyte TRPC6 channels by suPAR: Role of NADPH oxidases and Src family tyrosine kinases.
1/2018	Trpc6 inactivation confers protection in a model of severe nephrosis in rats.
5/2014	A mutation in TRPC6 channels abolishes their activation by hypoosmotic stretch but does not affect activation by diacylglycerol or G protein signaling cascades.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stuart E Dryer Research Topics

Disease

7	Segmental glomerulosclerosis 01/2022 - 05/2014
5	Fibrosis (Cirrhosis) 01/2022 - 01/2018
5	Kidney Diseases (Kidney Disease) 10/2021 - 05/2014
4	Glomerulonephritis 01/2022 - 08/2014
4	Diabetic Nephropathies (Diabetic Nephropathy) 10/2021 - 09/2011
4	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2019 - 08/2013
3	Ureteral Obstruction 01/2022 - 03/2019
3	Albuminuria 01/2022 - 01/2018
3	Body Weight (Weight, Body) 12/2019 - 10/2016
3	Chronic Renal Insufficiency 03/2019 - 04/2014
2	Inflammation (Inflammations) 01/2021 - 03/2019
2	Nephrosis 01/2018 - 10/2015
1	Acute Kidney Injury (Acute Renal Failure) 10/2021
1	Hyperglycemia 12/2019
1	Dyslipidemias (Dyslipidemia) 12/2019
1	Weight Gain 12/2019
1	Proteinuria 03/2019
1	Disease Progression 01/2019
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2019
1	Azotemia 01/2018
1	Hyperhomocysteinemia 10/2015
1	Wounds and Injuries (Trauma) 02/2015
1	Breast Neoplasms (Breast Cancer) 08/2011
1	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 10/2010
1	Melanoma (Melanoma, Malignant) 09/2007
1	Hypoxia (Hypoxemia) 03/2003

Drug/Important Bio-Agent (IBA)

9	TRPC6 Cation ChannelIBA 01/2022 - 10/2010
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2018
2	VimentinIBA 01/2021 - 03/2019
2	NitrogenIBA 12/2019 - 03/2019
2	CreatinineIBA 12/2019 - 03/2019
2	Urea (Carbamide)FDA LinkGeneric 12/2019 - 03/2019
2	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 10/2018 - 01/2017
2	Puromycin AminonucleosideIBA 01/2018 - 10/2015
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 10/2016 - 10/2015
1	Urokinase Plasminogen Activator ReceptorsIBA 10/2021
1	nephrinIBA 12/2019
1	C-PeptideIBA 12/2019
1	Streptozocin (Streptozotocin)FDA Link 12/2019
1	Immunoglobulin G (IgG)IBA 03/2019
1	Complement System Proteins (Complement)IBA 03/2019
1	AlbuminsIBA 01/2018
1	CholesterolIBA 01/2018
1	Triglycerides (Triacylglycerol)IBA 01/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017
1	Dizocilpine Maleate (Dizocilpine)IBA 10/2016
1	N-Methylaspartate (NMDA)IBA 10/2016
1	Memantine (Namenda)FDA Link 10/2016
1	Pharmaceutical PreparationsIBA 10/2015
1	statticIBA 02/2015
1	Transcription Factors (Transcription Factor)IBA 08/2014
1	Angiotensin IIIBA 04/2014
1	NPHS2 proteinIBA 08/2013
1	Transient Receptor Potential ChannelsIBA 08/2013
1	Insulin (Novolin)FDA Link 09/2011
1	Estrogen Receptor alphaIBA 08/2011
1	Estrogen ReceptorsIBA 08/2011
1	Potassium Channels (Potassium Channel)IBA 08/2011
1	Tamoxifen FDA LinkGeneric 08/2011
1	Estrogens (Estrogen)FDA Link 08/2011
1	FilaminsIBA 09/2007
1	Sodium-Activated Potassium ChannelsIBA 03/2003

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 10/2015
1	Therapeutics 08/2011